RNS Number:6443P
Henderson Morley PLC
11 September 2003


FOR IMMEDIATE RELEASE                                          11 SEPTEMBER 2003


                              HENDERSON MORLEY PLC

                                     (AIM)

                        Business: Drug Discovery Company

             ICVT - NEW PHASE II STUDY STARTS IN DERMAL APPLICATION



The Directors of Henderson Morley are pleased to announce that the Phase ll
study to examine the use of Ionic Contra Viral Therapy ("ICVT") against genital
warts in men has now received Ethics Committee approval and may now commence.



The study is under the supervision of Dr Humphrey Birley, a consultant in
genitourinary medicine, practicing at the Department of Genitourinary medicine
at the Cardiff Royal Infirmary in Cardiff.  Dr Birley's study will be examining
the safety and efficacy of ICVT in the treatment of genital warts in men.  Dr.
Birley is co-author of the National Guidelines for the treatment of genital
warts and has had numerous papers published on the subject.



Preliminary results are expected during the first half of 2004. The data created
by this study will be used to attract further commercial partners for the ICVT
platform.



This open label**, dose-escalating*** Phase ll study is directed against genital
warts in men that have proven resistant to other forms of treatment, which is
caused by the Human Papilloma Virus.



The Company believes success in this study should have important implications
for the treatment of these other conditions.



                                      ENDS



Copies of this announcement will be available free of charge to the public at
the Company's registered office at Metropolitan House, 2 Salisbury Road,
Moseley, Birmingham, B13 8JS and at the offices of Brewin Dolphin Securities
Ltd, 34 Lisbon Street, Leeds LS1 4LX for 14 days.



Enquiries:
HENDERSON MORLEY PLC                                 Tel: 0121 442 4600

Andrew Knight, Chairman
BREWIN DOLPHIN SECURITIES LTD                        Tel: 0113 241 0126

Neil Baldwin

BARNES AND WALTERS LTD                               Tel: 020 7430 1600
Maxine Barnes                                        Mobile 07860 489571

Notes to Editors:



** Open label studies are when the patient and the doctor treating them are both
aware of the drugs being used in the study.



*** Dose escalating studies are when the dose of the drug being used to treat
the patient is gradually increased from very low doses to higher doses,
depending on the clinical response.





About Human Papilloma Virus (HPV) infections

HPV is the name given to a group of more than 80 different strains of virus
associated with a variety of epidermal warts and skin lesions, some of which are
associated with cancer. Low risk sub types (type 6 and 11) are associated with
genital warts, but high risk subtypes (type 16 and 18) cause cancer of the
cervix and anus, and also cause dysplasias of anogenital tissues.





About Genital warts

Genital warts (a form of HPV infection) is one of the most common sexually
transmitted diseases in the world. The Centers for Disease Control and
Prevention (CDC) estimates close to 5.5 million new genital HPV cases occur each
year in the USA (approximately 2% of the population), which is approximately one
third of all sexually transmitted diseases. It is estimated that 24 million
people in the US are infected with HPV at any given time (approximately 10% of
the population). Again, in the US, nearly three out of four Americans between
the ages of 15 and 49 have been infected with genital HPV) in their lifetimes.
Approximately two thirds of people who have sexual contact with genital warts
will develop warts within 3 months of contact. (NIAID figures).



Figures for the incidence in South East Asia and other markets are more
difficult to determine, however the incidence in many developing countries far
exceed that of more developed nations.

The most commonly used treatments are essentially ablative, causing the
destruction of the infected tissues either chemically or physically. This often
causes a severe local inflammatory response which may be both painful and
cosmetically unacceptable.








                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RESKFLBFXKBZBBL